Table 3.

Comparison of outcomes by induction group

VariableAlemtuzumabBasiliximabATGP Value
Development of dnDSA at 1 yr, % (n)14 (12)5 (27)8 (14)0.0009
Graft survival at 1 yr, %10098990.81
Rejection at 1 yr, %
 AMR0.00.420.64
 ACR6550.66
CMV viremia at 1 yr, %3722380.0003
BK viremia at 1 yr, %
 BK >10002125240.45
 BK >10,0001517120.24
Delayed graft function, %4860.18
Length of hospital stay (d), mean±SD4.3±1.75.1±3.05.1±2.10.02
  • ATG, anti-thymocyte globulin; dnDSA, de novo donor-specific antibody; AMR, antibody-mediated rejection; ACR, acute cellular rejection; CMV, cytomegalovirus.